Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Intrexon
3127
Intrexon
Technology
Biotechnology
Health Care
Medical
Pharmaceuticals
Clinical Trials
Intrexon applies engineering principles to biology to enable products in the health, food, energy, consumer and environmental industries.
Suggest edits
Founded
1998
Raised
$319M
Follow us
Companies in the same industry
VG Life Sciences
Genomera
Oyster Point Pharma
Bristol-Myers Squibb
Neuraltus Pharmaceuticals
Pharmapod
G-CON
Mycodev Group
Atlantic Healthcare plc
PeptiMimesis
Alexa global traffic share
Twitter followers
Overview
Funding
6
Acquisitions
1
Apps
1
Add info
Latest funding
Show all
$57,500,000
Post-IPO equity - 2015
$150,000,000
Venture capital (Series F) - 2013
Randal J. Kirk
Team Size
1–10
Employees
I work here
Location
United States
Headquarters
Explore United States
Xconomy
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More
The Motley Fool
The $100 Million Platform Intrexon Investors Forgot
The Motley Fool
Why Intrexon Won't Commercialize Fuels by 2018
The Motley Fool
Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.
The Motley Fool
Intrexon Battles Thermodynamics, but Thermodynamics Always Wins
The Motley Fool
Intrexon vs. MosquitoMate: Who Has the Better Zika Tool?
The Motley Fool
Here's Why Intrexon Corporation Was All the Buzz in May
Health
Science
The Motley Fool
Regulatory Obstacles and Opportunities Facing Intrexon's Natural-Gas-to-Fuels Platform
The Motley Fool
Why Intrexon and Dominion Resources Are Excited About Natural Gas-to-Fuels
The Motley Fool
Intrexon's Risky Revenue Machine
The Motley Fool
Intrexon Delivers Revenue Growth (Again) While Avoiding Elephant in the Room
Earnings
Stock markets
The Motley Fool
Intrexon Corporation Shares Were Stung in April -- Here's Why
Health
Science
The Motley Fool
Is Intrexon Really a House of Cards?
Stock markets
Science
The Motley Fool
What's Behind Intrexon's Steep Sell-Off Today
The Motley Fool
3 Things Needed to Make Intrexon's Zika Virus Cure a Success
Health
The Motley Fool
Intrexon Corp. Shares Soar Again on Zika Virus Concerns
Health
Stock markets
The Motley Fool
Intrexon Corporation Catches Zika Fever
Health
Stock markets
The Motley Fool
The Likely Reason Behind Intrexon Corporation's Soaring Share Price --
Stock markets
Health
WIRED
Intrexon’s Billionaire CEO Is Betting on the Most Controversial GMOs
Science
